The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Treatment options for high-risk AML
Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, talks on attempts to improve treatment options for younger patients with high-risk acute myeloid leukemia (AML). Specifically discussed is the UK NCRI AML17 trial (ISRCTN55675535), comparing FLAG-Ida and daunorubicin with clofarabine for high-risk AML. Prof. Russell highlights the importance of early recognition of high-risk disease and reveals that optimizing induction and pre-stem cell transplant treatment allows more patients to get to transplant in remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
